Expression and significance of eHSP90α in peripheral blood of patients with coronary heart disease in Guangdong
-
摘要:
目的 探讨eHSP90α在冠心病发生发展中的作用和意义。 方法 选取2013年6月~2016年6月在本院住院的广东籍冠心病患者101例及对照组31例，收集病情资料，检测外周血eHSP90α含量。分析外周血eHSP90α含量与冠心病患者病情的关系。 结果 冠心病患者外周血中eHSP90α水平较对照组升高（P<0.01）。不稳定型冠心病患者外周血eHSP90α含量高于稳定性冠心病患者（92.17±23.63 ng/L vs 15.84±15.83 ng/L,P<0.01），冠心病合并心衰患者外周血eHSP90α含量高于不合并心衰发生的患者（93.04±22.94 ng/L vs 81.49±20.44 ng/L,P<0.05）。冠心病合并IV级、III级心衰患者外周血eHSP90α 差异没有统计学意义（P=0.158）。 结论 血中eHSP90α含量与广东地区冠心病患者病情相关，进一步深入研究也许可作为冠心病病情血学标志。 Abstract:Objective To investigate the effect of secreted Hsp90α (eHSP90α) on the development and progression of coronary heart disease (CHD). Methods A total of 101 patients with CHD and 31 cases as healthy control group were enrolled in this study from June 2013 to June 2016. The eHSP90 αlevels in peripheral blood of all cases were collected. The correlation of eHSP90α levels in peripheral blood with condition of patients with CHD was analyzed. Results The eHSP90α levels in peripheral blood of patients with CHD was significantly higher than that of healthy control group (P<0.01). In patients with CHD, eHSP90α levels in peripheral blood in unstable CHD group was significantly higher than that in stable CHD group (P<0.01). The eHSP90α levels in peripheral blood in CHD combined with heart failure was significantly higher than that in patients group without heart failure (P<0.05). The eHSP90α levels in peripheral blood of CHD patients with grade Ⅳ heart failure had no significant difference with grade III heart failure patients (P=0.158). Conclusion The eHSP90α levels in peripheral blood are closely related to the condition of CHD in Guangdong. It may be a serological marker of coronary heart disease by further study. -
Key words:
- coronary heart disease /
- eHSP90α /
- heart failure
-
表 1 稳定型和不稳定型冠心病患者基本情况和血eHSP90α含量
组别 n 男/女 年龄（岁） eHSP90α (ng/L) 健康对照组 31 10/21 69.12±13.12 63.95±22.50 稳定型 51 34/17 67.95±10.74 15.84±15.83 不稳定型 50 30/20 71.29±9.25 92.17±23.63 P 0.711 0.306 0.00 
下载: 导出CSV
表 2 不同冠脉病变分型冠心病患者基本情况和血eHSP90α含量
组别 n 男/女 年龄（岁） eHSP90α (ng/L) 健康对照组 31 10/21 69.22±13.12 63.95±22.50 A组 35 20/15 70.36±10.12 75.92±19.06 B1组 30 10/20 67.22±10.61 83.07±16.10 B2组 21 7/14 72.23±7.73 88.52±20.95 C组 15 10/5 69.43±11.36 99.31±28.85 P 0.895 0.704 0.00
下载: 导出CSV
表 3 不同冠脉病变支数冠心病患者基本情况和血eHSP90α含量
组别 n 男/女 年龄（岁） eHSP90α (ng/L) 健康对照组 31 10/21 69.22±13.12 63.95±3.32 一支冠脉病变 43 30/13 68.08±11.42 76.15±15.89**△ 两支冠脉病变 36 22/14 70.31±9.04 86.47±20.21*△ 三支冠脉病变 22 12/10 71.16±9.28 93.51±27.50△ P 0.619 0.283 0.00 *P<0.05 vs SV; **P<0.01 vs MV; △P<0.01 vs对照组.
下载: 导出CSV
表 4 合并心衰和不合并心衰的冠心病患者血eHSP90α含量
组别 n 男/女 年龄（岁） eHSP90α (ng/L) 冠心病不合并心衰患者 79 52/27 69.56±10.88 81.49±20.44 冠心病合并心衰 22 11/11 70.23±80.80 93.04±22.94 P 0.063 0.791 0.041
下载: 导出CSV
表 5 不同心功能级别的冠心病合并心衰患者血eHSP90α含量
组别 n 男/女 年龄 eHSP90α (ng/L) III 13 7/6 67.85±9.53 87.33±23.36 IV 9 4/5 73.67±6.89 101.29±20.81 P 0.453 0.211 0.158
下载: 导出CSV
-
[1] Hashmi S, Ahmad HR, Sharif H, et al. Diastolic dysfunction in coronary artery disease[J]. J Coll Physicians Surg Pak, 2017, 27(3): 192. [2] Senior R, Khattar RS. Cardiac investigation for prognosis in coronary artery disease: where negative is positive[J]. Eur Heart J Cardiovasc Imaging, 2017, 25(8): 25. [3] Fan J, Ma J, Xia N, et al. Clinical value of combined detection of CK-MB, MYO, cTnI and plasma NT-proBNP in diagnosis of acute myocardial infarction[J]. Clin Lab, 2017, 63(3): 427-33. [4] Moludi J, Keshavarz S, Tabaee AS, et al. Q10 supplementation effects on cardiac enzyme CK-MB and troponin in patients undergoing coronary artery bypass graft: a randomized, double-blinded, placebo-controlled clinical trial[J]. J Cardio Thorac Res, 2016, 8(1): 1-7. doi: 10.15171/jcvtr.2016.01 [5] Walter R, Pan KT, Doebele C, et al. HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling[J]. Blood, 2017, 129(5): 598-608. doi: 10.1182/blood-2016-06-721423 [6] Zou M, Bhatia A, Dong H, et al. Evolutionarily conserved dual lysine motif determines the non-chaperone function of secreted Hsp90alpha in tumour progression[J]. Oncogene, 2017, 36(15): 2160-71. doi: 10.1038/onc.2016.375 [7] Bhatia A, O'brien K, Chen M, et al. Keratinocyte-Secreted heat shock protein-90alpha: leading wound reepithelialization and closure[J]. Advances Wound Care, 2016, 5(4): 176-84. doi: 10.1089/wound.2014.0620 [8] Blair LJ, Sabbagh JJ, Dickey CA. Targeting Hsp90 and its co-chaperones to treat Alzheimer's disease[J]. Expert Opin Ther Targets, 2014, 18(10): 1219-32. doi: 10.1517/14728222.2014.943185 [9] Calderwood SK, Gong J. Heat shock proteins promote cancer: it's a protection racket[J]. Trends Biochem Sci, 2016, 41(4): 311-23. doi: 10.1016/j.tibs.2016.01.003 [10] Vladic N, Ge ZD, Leucker T, et al. Decreased tetrahydrobiopterin and disrupted association of Hsp90 with eNOS by hyperglycemia impair myocardial ischemic preconditioning[J]. Am J Physiol Heart Circ Physiol, 2011, 301(5): H2130-9. doi: 10.1152/ajpheart.01078.2010 [11] Gao ZM, Liu FH, Yin P, et al. Inhibition of heat-induced apoptosis in rat small intestine and IEC-6 cells through the AKT signaling pathway[J]. BMC Vet Res, 2013, 9(8): 241. [12] 朱惠民, 曾高峰. 冠心病患者血清热休克蛋白90水平变化及意义[J]. 实用医学杂志, 2009(04): 576-7. doi: 10.3969/j.issn.1006-5725.2009.04.026 [13] 刘代华, 黄红林, 廖端芳. 热休克蛋白90在心血管系统中的作用[J]. 国外医学: 生理, 病理科学与临床分册, 2004(05): 473-5. http://www.cnki.com.cn/Article/CJFDTOTAL-WYSB200405023.htm [14] García R, Merino D, Gómez JM, et al. Extracellular heat shock protein 90 binding to TGFβ receptor I participates in TGFβ-mediated collagen production in myocardial fibroblasts[J]. Cell Signal, 2016, 28(10): 1563-79. doi: 10.1016/j.cellsig.2016.07.003 [15] Hance MW, Dole K, Gopal U, et al. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer[J]. J Biol Chem, 2012, 287(45): 37732-44. doi: 10.1074/jbc.M112.389015 [16] Nolan KD, Franco OE, Hance MW, et al. Tumor-secreted Hsp90 subverts polycomb function to drive prostate tumor growth and invasion[J]. J Biol Chem, 2015, 290(13): 8271-82. doi: 10.1074/jbc.M115.637496 [17] Dong H, Zou M, Bhatia A, et al. Breast Cancer MDA-MB-231 cells use secreted heat shock protein-90alpha (Hsp90α) to survive a hostile hypoxic environment[J]. Sci Rep, 2016, 6(4): 20605. [18] Bohonowych JE, Hance MW, Nolan KD, et al. Extracellular Hsp90 mediates an NF-κB dependent inflammatory stromal program: implications for the prostate tumor microenvironment[J]. Prostate, 2014, 74(4): 395-407. doi: 10.1002/pros.v74.4 [19] Tukaj S, Węgrzyn G. Anti-Hsp90 therapy in autoimmune and inflammatory diseases: a review of preclinical studies[J]. Cell Stress Chaperones, 2016, 21(2): 213-8. doi: 10.1007/s12192-016-0670-z [20] Ocaña GJ, Pérez L, Guindon L, et al. Inflammatory stress of pancreatic beta cells drives release of extracellular heat-shock protein 90α[J]. Immunology, 2017, 151(2): 198-210. doi: 10.1111/imm.2017.151.issue-2 -
点击查看大图
表(5)
计量
- 文章访问数: 473
- HTML全文浏览量: 188
- PDF下载量: 1
- 被引次数: 0
